Introduction

Cartilage helps joints move smoothly. When it wears or is damaged, pain and stiffness can follow — and the usual options do not always provide lasting relief. This article looks at how newer non-surgical approaches, particularly the ChondroFiller collagen injection, are changing what is possible in joint care, while keeping expectations realistic throughout.

Why Joint Wear Is Challenging

Articular cartilage has a limited blood supply, which means it heals slowly and incompletely after injury or gradual wear. Even minor damage can lead to persistent pain because the cartilage cannot readily restore itself. This biological limitation is why there is genuine interest in treatments that aim to support the joint directly, rather than simply masking symptoms.

Why Conventional Treatments Can Fall Short

Rest, analgesia, and physiotherapy remain important first-line measures that can ease discomfort and improve function. For many people, however, pain returns once loading resumes, and the underlying surface damage is unchanged. It is in this gap — between simple symptom management and joint replacement — that biologics and regenerative injections are increasingly used.

ChondroFiller: A Non-Surgical Collagen Injection

ChondroFiller is a CE-marked Class III medical device — a type I collagen hydrogel scaffold produced by Meidrix Biomedicals, Germany, and imported into the UK under prescription. When given as a non-surgical, ultrasound-guided outpatient injection, it is delivered directly into the joint without a theatre setting, incision, or general anaesthetic.

Once inside the joint, the liquid collagen self-gels within a few minutes, forming a porous three-dimensional matrix that settles over the worn or damaged surface. The scaffold is acellular — it contains no donor cells — and instead recruits the patient's own progenitor cells from the surrounding tissue. These cells can migrate into the matrix and, over months, remodel it towards cartilage-like tissue.

In published clinical studies, patients treated with ChondroFiller have shown meaningful improvements in function and pain scores at twelve to thirty-six months, with MOCART imaging scores (which assess the quality and fill of repaired tissue) in the range of around 80 and above in knee and hip series. ChondroFiller is intended for ICRS Grade I–IV cartilage defects up to approximately 6 cm2 across a range of joints, including the knee, hip, ankle, and small joints of the hand. It is not a cure for arthritis, and results vary between individuals.

A Surgical Option: The Liquid Cartilage Protocol

Not every patient or every defect is suited to an injection-based approach. For larger or load-bearing defects — particularly in the knee, hip, shoulder, or ankle — a keyhole surgical procedure called the Lee Liquid Cartilage Protocol may be more appropriate. Liquid Cartilage is not a different material; it is Professor Paul Lee's surgical technique, which places the ChondroFiller scaffold arthroscopically and combines it with biological adjuncts including platelet-rich fibrin, platelet-rich plasma, tranexamic acid, and — where indicated — the patient's own mesenchymal stem cells from bone marrow or micro-fragmented fat. This is genuine surgery requiring a theatre, anaesthetic, and a structured rehabilitation programme. The two pathways — injection and keyhole surgery — serve different indications and are assessed individually.

The Value of Accurate Assessment

Neither the ChondroFiller injection nor the Liquid Cartilage surgical protocol is suitable for every person or every joint. The decision depends on the size and depth of the cartilage defect, the joint involved, the degree of underlying osteoarthritis, the patient's activity goals, and overall health. An accurate diagnosis — typically combining clinical examination with MRI — is essential before any regenerative treatment is considered. Realistic expectations are part of that assessment: these are joint-preservation options, not procedures that reverse established arthritis.

Conclusion

Because articular cartilage heals poorly on its own, joint wear can cause lasting problems that conventional measures do not fully address. The ChondroFiller non-surgical injection offers one route to supporting the joint — adding a regenerative collagen scaffold without a theatre or incision. For patients with larger defects or more complex anatomy, the Liquid Cartilage keyhole surgical protocol provides a more intensive biological approach. Both represent a meaningful step forward from purely symptomatic treatment, and both require careful specialist selection. Always seek advice from a qualified healthcare professional before pursuing any of these options.

At the London Cartilage Clinic, assessments are carried out to establish which pathway, if either, may be appropriate — with honest guidance throughout.

References

Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.